Sky View Investment Advisors, LLC Abb Vie Inc. Transaction History

Sky View Investment Advisors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 16, 2023	SELL	$133.59 - $154.65 $285,481 - $330,487	-2,137 Reduced 95.96%	90 $13,000
Q2 2023 Aug 15, 2023	BUY	$132.51 - $164.9 $3,710 - $4,617	28 Added 1.27%	2,227 $300,000
Q1 2023 May 18, 2023	BUY	$144.61 - $166.54 $8,098 - $9,326	56 Added 2.61%	2,199 $350,000
Q4 2022 Feb 16, 2023	SELL	$138.31 - $165.87 $133,884 - $160,562	-968 Reduced 31.12%	2,143 $346,000
Q3 2022 Nov 16, 2022	BUY	$134.21 - $153.93 $37,578 - $43,100	280 Added 9.89%	3,111 $418,000
Q2 2022 Nov 15, 2022	BUY	$137.62 - $174.96 $100,187 - $127,370	728 Added 34.62%	2,831 $434,000
Q1 2022 May 17, 2022	SELL	$131.98 - $163.75 $15,441 - $19,158	-117 Reduced 5.27%	2,103 $322,000
Q4 2021 Feb 18, 2022	BUY	$107.43 - $135.93 $238,494 - $301,764	2,220 New	2,220 $300,000
Q1 2021 May 18, 2021	SELL	$102.3 - $112.62 $221,172 - $243,484	-2,162 Closed	0 $0
Q4 2020 Mar 02, 2021	BUY	$80.49 - $108.67 $174,019 - $234,944	2,162 New	2,162 $232,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $317B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Sky View Investment Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Sky View Investment Advisors, LLC with notifications on news.